Stocklytics Platform
Asset logo for symbol XLO
Xilio Therapeutics
XLO53
$1.01arrow_drop_up5.31%$0.05
Penny Stock
Asset logo for symbol XLO
XLO53

$1.01

arrow_drop_up5.31%

Performance History

Chart placeholder
Key Stats
Open$0.99
Prev. Close$0.95
EPS-2.57
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$35.39M
PE Ratio-
LOWHIGH
Day Range0.93
1.01
52 Week Range0.49
2.94
Ratios
Revenue-
EBITDA Margin %-
EPS-2.57

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

Correlated Companies

Price$804.62
Perf. (24h)
arrow_drop_down2.01%-$16.57
Market Cap$738.87B
Price$569.71
Perf. (24h)
arrow_drop_up1.79%$10.03
Market Cap$527.83B
Price$160.64
Perf. (24h)
arrow_drop_up0.62%$1.00
Market Cap$386.60B
Price$185.16
Perf. (24h)
arrow_drop_up1.64%$2.99
Market Cap$326.96B

About Xilio Therapeutics (XLO)

Xilio Therapeutics, Inc. (XLO) is a biopharmaceutical company focused on developing targeted immunotherapies for cancer treatment. The company's mission is to leverage its proprietary technology platform, which combines tumor cell-selective potent immune activation with localized therapeutic payload delivery, to revolutionize cancer treatment. Xilio Therapeutics is headquartered in Boston, Massachusetts and was founded in 2016.
Xilio Therapeutics' lead product candidate, XTX101, is a novel immunotherapy designed to activate a patient's immune system to target and destroy cancer cells. XTX101 is currently being evaluated in a Phase 1/2 clinical trial for the treatment of solid tumors. The company's approach is based on the concept of using a tumor-selective immunostimulant to activate immune cells specifically at the tumor site, while sparing normal tissues from immune activation.
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Rene Russo BCPS, Pharm.D, Pharm.D.
Headquarters
Waltham
Employees
84
Exchange
NASDAQ
add Xilio Therapeutics to watchlist

Keep an eye on Xilio Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is the 52-week high and low for Xilio Therapeutics (XLO)?
For Xilio Therapeutics (XLO), the 52-week high is $2.94, which is 191.09% from the current price. The 52-week low is $0.49, the current price is 106.12% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help
What is Xilio Therapeutics's (XLO) price per share?
The current price per share for Xilio Therapeutics (XLO) is $1.01. The stock has seen a price change of $0.05 recently, indicating a 5.32% change. This reflects the stock's recent market performance and investor sentiment.
help
Is Xilio Therapeutics (XLO) a growth stock?
Xilio Therapeutics (XLO) has shown an average price growth of 0.41% over the past three years. It has received a score of 10 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Xilio Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help
What is Xilio Therapeutics (XLO) stock price performance year to date (YTD)?
As of the latest data, Xilio Therapeutics (XLO) has a year-to-date price change of 75.65%. Over the past month, the stock has experienced a price change of 10.73%. Over the last three months, the change has been -7.34%. Over the past six months, the figure is 55.38%.
help
Is Xilio Therapeutics (XLO) a profitable company?
Xilio Therapeutics (XLO) has a net income of -$76.4M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$79.13M. Furthermore, the EBITDA is -$70.3M.
help
What is the market capitalization of Xilio Therapeutics (XLO)?
Xilio Therapeutics (XLO) has a market capitalization of $35.4M. The average daily trading volume is 96.06K, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level